Progress, Potential, and Possibilities Podcast / Show

Send us a textSusan Bratton (https://susanbratton.com/), is an Intimacy Wellness Expert, Sexual Bio-Hacker, and self-proclaimed "Orgasmanaut", who is a champion and advocate for all those who desire life long intimacy and passion. Susan is co-founder and CEO of two corporations: Personal Life Media, Inc., a publisher of heart-connected lovemaking techniques and bedroom communication skills, and The20, LLC., a manufacturer of organic and botanical supplements that enhance sexual vitality. Susan is a best-selling author and publisher of 34 books and programs including Sexual Soulmates, Relationship Magic, Revive Her Drive, Ravish Him, Steamy Sex Ed™, The Passion Patch, Hormone Balancing, and Hot To Trot. Susan is currently an official company spokesperson for both The Anti-Aging Group, LLC's GAINSWave®️ protocol, and The Dr. Joel Kaplan Inc. brand of vacuum erection devices. Her book, Pump Guide, has helped over 30,000 men regain their sexual performance in midlife and beyond. Susan has been featured in the New York Times and on CNBC and the TODAY show as well as frequent appearances on ABC, CBS, The CW, Fox and NBC. You can find The Susan Bratton Show® at BetterLover.com, her personal shares on Instagram @susanbratton, her lust-for-life supplements, FLOW and DESIRE at The20store.com, and her Expanded Orgasm Couples Practice guides at https://expandherorgasmtonight.com/Support the show

Send us a textDonato Tramuto is a healthcare executive, global health activist, and author who is widely recognized for his commitment to social change and transformational leadership in healthcare innovation. Mr. Tramuto is the Founder and Chair of The TramutoPorter Foundation (https://tramutofoundation.com/) which advances young people’s rights to education and healthcare access and combats human right violations. Mr. Tramuto's three-decade commitment to social change and innovation has earned numerous awards, including both the prestigious Robert F. Kennedy Ripple of Hope and the RFK Embracing His Legacy Awards, and he currently serves as a member of the board of Robert F. Kennedy Human Rights and is Chairman of its Leadership Council where his foundation has committed to funding a three-year, $1 million grant to address workplace bullying, leading a national initiative to address workplace dignity and inclusion in the U.S. and Europe. Mr. Tramuto is a passionate champion of cutting-edge approaches to healthcare access, drug safety, and addressing the social determinants of health (SDOH), defined by the World Health Organization as the conditions in which people are born, grow, live, work and age. Mr. Tramuto has a long record of bringing together social commitment with healthcare innovation, including roles as CEO of Tivity Health, a provider of health improvement, fitness and social engagement solutions, and founder of Physicians Interactive Holdings (Aptus Health sold to WebMD in 2019), a global provider of insight-driven digital engagement solutions for healthcare professionals and consumers. Reflecting a conviction that universal healthcare is a basic human right for all people, he launched Health eVillages in 2011, a non-profit organization providing state-of-the-art mobile health technology in the most challenging clinical environments and working to broaden healthcare access. Mr. Tramuto is a member of the Brown University Healthcare Leadership Board, as well as a member of the Advisory Board of Boston University School of Public Health. He is a member of the Board of Directors of the Livongo Health Foundation, Sharecare, Inc., Cherish Health Inc., Robert F. Kennedy Human Rights, Robert F Kennedy Human Rights Europe, Health eVillages, and the Gryphon Investment Executive Advisory Board. He is the mastermind behind a groundbreaking 360° public service campaign and annual summit addressing challenges unique to older adults, including the too-often overlooked issues of isolation and loneliness. A proponent of lifelong learning, Mr. Tramuto holds honorary doctorates from the University of Massachusetts at Lowell, Thomas Jefferson University, Lasell College and Saint Joseph’s College, and is the author of Life’s Bulldozer Moments: How Adversity Leads to Success in Life and Business. Mr. Tramuto’s second book, The Double Bottom Line, How Compassionate Leaders Captivate Hearts and Deliver Results, will be released in April of 2022.Support the show

Send us a textDr. Joseph D. Mocanu, Ph.D. (https://www.vergehc.com/team) is the Managing Partner of the Verge HealthTech Fund, focusing on early stage healthcare technology companies relevant to emerging markets. Dr. Mocanu started his career as a scientist, developing new cancer therapies during his Ph.D. at the University of Toronto. He co-founded a medical device startup during his studies which brought him into the world of business and his first interactions with VCs. Dr. Mocanu first learned about active investing during his time at DM Capital in Shenzhen, helping launch their first fund, Harmony. He then joined Oliver Wyman’s health and life sciences practice to understand and develop strategies towards addressing key business and market needs for his global healthcare clients, and did so for over 75 projects, and across 20+ markets. During this time he also assisted several funds and conglomerates with their healthcare investment strategies. Seeing the need for more early stage investment for healthcare founders, and the opportunity for technology to make a real difference, Dr. Mocanu began angel investing in health tech companies in 2014, eventually reaching a personal portfolio of 9 companies by 2018. It was at that point that he realized that he needed to do this full time and that there weren't any funds that were focused on seed stage, health tech, and massive solving global problems, which is when he decided to launch Verge HealthTech later that year. Dr. Mocanu has a Ph.D. in medical biophysics from the University of Toronto, and an MBA from the Richard Ivey School of Business, Western University, specializing in the Health Sector and Entrepreneurship. Support the show

Send us a textDr. Sanjoy Dutta, PhD, is the Chief Scientific Officer at JDRF International (https://www.jdrf.org/) a nonprofit organization that funds Type 1 Diabetes (T1D) research, provides a broad array of community and activist services to the T1D population, and actively advocates for regulation favorable to medical research and approval of new and improved treatment modalities. Dr. Dutta oversees all of JDRF’s efforts to cure Type 1 Diabetes and improve the lives of those living with it, which includes beta cell therapies, immunotherapies, glucose control and related disease complications. He is also responsible for international partnerships with world-leading government, non-government, foundation and commercial organizations. Dr. Dutta joined JDRF in 2009. Prior to coming to JDRF, Dr. Dutta was the Associate Director of Translational Medicine and Clinical Biomarkers at Bristol-Myers Squibb, and Principal Scientist of Cardiovascular and Metabolic Diseases at Hoffmann-La Roche. Dr. Dutta obtained his doctorate from the department of biochemistry and molecular biology at the University of Southern California and was a JDRF Postdoctoral Fellow in the department of cell biology and the Joslin Diabetes Center at Harvard Medical School.Support the show

Send us a textDr. David K. C. Cooper, MA, PhD, MD, MS, DSc (Med), FRCS, FACS, FACC, FAST, (https://researchers.mgh.harvard.edu/profile/27073950/David-Cooper) is a pioneering heart transplant surgeon and researcher in the field of xenotransplantation, which is defined as any procedure that involves the transplantation, implantation or infusion into a human recipient of live cells, tissues, or organs from a nonhuman animal source. Dr. Cooper studied medicine in the UK at Guy’s Hospital Medical School (now part of King’s College London), and trained in general and cardiothoracic surgery in Cambridge and London. Between 1972 and 1980, Dr. Cooper was a Fellow and Director of Studies in Medical Sciences at Magdalene College, Cambridge. In 1980 he took up an appointment in cardiac surgery at the University of Cape Town where, under Professor Christiaan Barnard, he had responsibility for patients undergoing heart transplantation. In 1987, Dr. Cooper relocated to the Oklahoma Transplantation Institute in the USA where he continued to work in both the clinical and research fields. After 17 years as a surgeon-scientist, he decided to concentrate on research, initially at the Massachusetts General Hospital/Harvard Medical School in Boston, subsequently at the University of Pittsburgh, and then at the University of Alabama at Birmingham, where his major interest was in developing cross-species transplantation with the aim of using pigs as sources of organs, cells, and corneas for transplantation in humans. He currently continues his research programs at the Massachusetts General Hospital/Harvard Medical School. Dr. Cooper has published almost 1,000 medical and scientific papers and chapters, has authored or edited 18 books, has given more than 350 invited presentations worldwide, and has received several awards for his work.Support the show

Send us a textDr. Kevin Perrott, Ph.D. is Founder and CEO, OpenCures (https://opencures.org/), Adjunct Professor, University of Alberta, Co-Founder and Advisor, Oisin Biotechnologies, President, of Global Healthspan Policy Institute, and Co-Founder and Treasurer, SENS Research Foundation. Kevin is a successful entrepreneur and owner of the largest motorcycle and snowmobile dealership in Canada, Riverside Honda and Skidoo Sales in Edmonton, Alberta. He became a cancer survivor, an experience which clearly highlighted the deficiencies of the current health technology development paradigm where the customer has almost no input in the development of their own health solutions. Armed with the realization that nothing is more valuable than health and the time to enjoy it with those you love, Kevin resolved to put his energies towards addressing these deficiencies. In 2003, Kevin joined Aubrey de Grey and David Gobel to form the Methuselah Foundation which offered competitive prizes for advances in longevity science. A few years later he became a co-founder with Aubrey de Grey and others of SENS Research Foundation to develop interventions able to repair or make harmless the damage that accumulates and underlies multiple age-related disorders. Mostly recently, Kevin formed OpenCures as a for-benefit corporation helping individuals perform self-directed research, generate data, and focus the value of data on the health solutions they are interested in. Kevin has authored and co-authored several peer-reviewed articles all focused on accelerating the science underlying the development of therapies for degenerative diseases. He is a co-founder of multiple non-profit and for-profit entities whose missions are aligned with that purpose. Kevin has a PhD in Biomedical Engineering from University of Alberta, with work performed at the Campisi Lab of the Buck Institute studying the effects of natural compounds on senescence, as well as a BSc, Double Major, in Biology and Chemistry.Support the show

Send us a textAlistair Fulton (https://www.semtech.com/company/executive-leadership/alistair-fulton) is the Vice President and General Manager of Semtech's Wireless and Sensing Products Group. Semtech Corporation is a supplier of analog and mixed-signal semiconductors and advanced algorithms for consumer, enterprise computing, communications and industrial end-markets. It has 32 locations in 15 countries in North America, Europe, and Asia. Semtech is the developer of LoRa, a long-range networking initiative for the Internet of Things. As of March 2021, over 178 million devices use LoRa worldwide. LoRa has been used in satellites, tracking of animals, and natural disaster prediction. Mr. Fulton joined Semtech in 2018 with over 25 years of experience in the Internet of Things (IoT), connected devices, machine to machine (M2M)/embedded, and analytics spaces. Before joining Semtech, Mr. Fulton led the development of Hitachi's Lumada Industrial IoT Platform, the leading "visionary" IIoT platform in Gartner's 2018 magic quadrant. Prior to Hitachi, he led Microsoft's early IoT initiatives, including the development and incubation of Microsoft's v1.0 IoT platform (the precursor to the v3.0 Azure IoT platform). Mr. Fulton also served as a Leader within Deloitte Consulting's Strategy & Operations / Telecommunications Media and Technology practice, focused on new product development, innovation and strategic transformation engagements in the wireless & Internet of Things (IoT) sectors. He started his career at Telefónica UK.Support the show

Send us a textAnna Farberov is General Manager at PepsiCo Labs (https://labs.pepsico.com/), where she focuses on investments and partnerships in the areas of Tech Venturing, Value Chain, Data & Analytics, Machine Learning / Artificial Intelligence (ML/AI) and Sustainability, and via their investments in the start-up community, works with entrepreneurs to co-develop products and services for PepsiCo, Inc. the American multinational food, snack, and beverage corporation. Prior to PepsiCo Labs, Anna spent 7 years at P&G in finance and business development roles, as well as 2 years as Head of Strategy and Planning at Discount Investment Corp Ltd., Israel's leading holding company operating in the fields of Real Estate, Telecommunications, Technology, Agriculture, and Asset Management. As the leader of PepsiCo Labs engagements with cutting edge technology and investments in startups globally, Anna is at the forefront of PepsiCo’s planning for the future. Given her extensive experience in finance, business strategy, innovation and Consumer Packaged Goods, she brings invaluable perspective and insights to the startups in PepsiCo Labs. Fluent in three languages, and an avid relationship builder, Anna partners with PepsiCo’s senior leaders to create value for both PepsiCo and startups. Anna has a Bachelor of Arts (B.A.) in Philosophy, Politics and Economics from The Hebrew University of Jerusalem, and a Master of Business Administration (MBA), with a focus in Finance from Reichman University (IDC Herzliya).Support the show

Send us a textKeren Haruvi is President of Sandoz US and Head of their North America business (https://www.novartis.us/about-us/our-leadership/us-country-leadership/keren-haruvi). Sandoz is a division of the Novartis Group and a global leader in generic pharmaceuticals and biosimilars and was established in 2003, when Novartis united all of its generics businesses under the name Sandoz – a single global brand with a long history. Since then, Sandoz has grown into a leading global generics business with annual sales of approximately US$10 billion. In her current role, Keren leads Sandoz’ largest commercial and country organization – the United States – which is responsible for over 35% of Sandoz global revenue. She also oversees Sandoz commercial operations in Canada. In addition to serving on the Novartis Country Leadership Team, Keren is a member of the Global Sandoz Executive Committee. Prior to joining Sandoz, Keren served as Global Head of M&A at Novartis International AG. Her early career began at Teva Pharmaceutical Industries where she steadily advanced in leadership roles to Senior VP, Global Business Development and Alliance Management. Keren is a value creator in the biopharmaceutical space, and brings close to 20 years of experience in the pharmaceutical industry, marked by success leading major M&A deals, enterprise innovations, and complex market strategies for large-scale, sustainable growth. Keren holds an MBA in Finance from Bar Ilan University and a Bachelor’s degrees in Economics and Chemistry from Tel Aviv University. Nominated for Top 40 Under 40 in The Marker magazine, she exemplifies the insight and wisdom needed to move global organizations forward. Outside of work, Keren enjoys spending time with her 5 children. She is an avid runner with one marathon and 3 half-marathons under her belt.Support the show

Send us a textDr. Ashani Weeraratna, Ph.D., (https://publichealth.jhu.edu/faculty/3918/ashani-t-weeraratna) is Bloomberg Distinguished Professor, Chair, Biochemistry & Molecular Biology, and Professor, Johns Hopkins Bloomberg School of Public Health. Dr. Weeraratna is also a recently appointed member (by President Joe Biden), of the National Cancer Advisory Board (https://deainfo.nci.nih.gov/advisory/ncab/ncab.htm), which advises and assists the director of the National Cancer Institute on the activities of the national cancer program. Dr. Weeraratna is a groundbreaking researcher exploring crucial questions about the role aging plays in cancer and her findings on age-related differences in responses to both targeted therapy and immuno-therapy for cancer are leading to a change in clinical practice. Dr. Weeraratna studies the molecular mechanisms involved in metastasis and how tumor micro-environments affect melanoma progression and therapy resistance. She is interested in how the aging micro-environment guides changes leading to increased metastasis and therapy resistance, as well as cell-autonomous aspects of therapy resistance. Dr. Weeraratna’s research also encompasses biophysical changes that affect the ability of both tumor and immune cells to migrate. She has demonstrated that normal age-related changes in the micro-environment can contribute to multiple aspects of melanoma formation and development as well as therapy resistance. Dr. Weeraratna’s work in melanoma prevention includes a public health approach. She recently helped lead a campaign to introduce sunblock dispensers throughout Philadelphia and talk to children about the dangers of tanning. Dr. Weeraratna is also the author of Is Cancer Inevitable? which clearly describes cancer’s mechanisms and how teams like hers are finding ways to reduce its deadly impacts. The book is part of the Johns Hopkins Wavelengths series. Dr. Weeraratna joined Johns Hopkins University as a Bloomberg Distinguished Professor in 2019 from the Wistar Institute where she established her lab back in 2011, and prior to that was at the National Institute on Aging, since 2003. Dr. Weeraratna earned a doctorate in Molecular and Cellular Oncology from George Washington University Medical Center and completed post-graduate training and was a postdoctoral fellow in experimental therapeutics and pharmacology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, then known as the Johns Hopkins Oncology Center. Support the show